20 May 2013
Keywords: reports, cv, toxicity, emerge, novartis, wonder, anticancer
Article | 31 July 2006
New data published in the journal Nature Medicine suggest that Novartis'Gleevec (imatinib mesylate; sold in Europe as Glivec) may lead
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
31 July 2006
17 May 2013
© 2013 thepharmaletter.com